| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC39A6 |
| Uniprot No | Q13433 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-325aa |
| 氨基酸序列 | FPQTTEKISPNWESGINVDLAISTRQYHLQQLFYRYGENNSLSVEGFRKLLQNIGIDKIKRIHIHHDHDHHSDHEHHSDHERHSDHEHHSEHEHHSDHDHHSHHNHAASGKNKRKALCPDHDSDSSGKDPRNSQGKGAHRPEHASGRRNVKDSVSASEVTSTVYNTVSEGTHFLETIETPRPGKLFPKDVSSSTPPSVTSKSRVSRLAGRKTNESVSEPRKGFMYSRNTNENPQECFNASKLLTSHGMGIQVPLNATEFNYLCPAIINQIDARSCLIHTSEKKAEIPPKTYSLQIAW |
| 预测分子量 | 35.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SLC39A6(ZIP6)重组蛋白研究的示例参考文献(内容基于领域研究背景概括，非真实文献)：
1. **文献名称**：*Expression and Purification of Human SLC39A6 in HEK293 Cells for Functional Zinc Transport Studies*
**作者**：Chen L, et al.
**摘要**：报道了人源SLC39A6重组蛋白在哺乳动物细胞(HEK293)中的真核表达系统构建，通过亲和层析纯化获得高纯度蛋白，并验证其体外锌离子转运活性。
2. **文献名称**：*Structural Insights into SLC39A6 Protein via Recombinant Crystallography*
**作者**：Smith KJ, et al.
**摘要**：利用大肠杆菌重组表达系统获得SLC39A6跨膜结构域的可溶性蛋白，通过X射线晶体学解析其三维结构，揭示锌离子结合的关键氨基酸位点。
3. **文献名称**：*SLC39A6 Recombinant Protein Modulates Epithelial-Mesenchymal Transition in Breast Cancer Cells*
**作者**：Wang Y, et al.
**摘要**：通过体外实验证明，重组SLC39A6蛋白通过调控细胞内锌稳态，影响乳腺癌细胞中EMT相关信号通路(如TGF-β)，提示其潜在肿瘤调控机制。
(注：以上文献为模拟示例，实际研究需通过PubMed/Google Scholar检索真实文献。)
SLC39A6. also known as ZIP6. is a member of the solute carrier family 39 (SLC39A) of zinc transporters. This protein plays a critical role in cellular zinc homeostasis by facilitating zinc influx into the cytoplasm from extracellular or intracellular compartments. Zinc, an essential trace element, is vital for numerous biological processes, including enzymatic activity, signal transduction, and gene regulation. SLC39A6 is characterized by its eight transmembrane domains and a histidine-rich motif, which is thought to mediate zinc binding and transport. Dysregulation of SLC39A6 has been implicated in various pathological conditions, particularly cancer. Overexpression of SLC39A6 has been observed in multiple malignancies, such as breast, liver, and gastric cancers, where it promotes tumor progression, metastasis, and chemoresistance by enhancing epithelial-mesenchymal transition (EMT) and activating oncogenic signaling pathways like STAT3 and MAPK.
Recombinant SLC39A6 protein is engineered using heterologous expression systems, such as Escherichia coli or mammalian cell lines, to produce a purified, functionally active form of the protein for research applications. The recombinant protein retains the native structure and zinc-transporting activity, enabling studies on its biochemical properties, interaction partners, and regulatory mechanisms. Its production often involves affinity tags (e.g., His-tag) for efficient purification and detection. Researchers utilize recombinant SLC39A6 to investigate its role in zinc metabolism, cellular proliferation, and cancer biology. Additionally, it serves as a critical tool for developing targeted therapies, screening inhibitors, and generating antibodies. Understanding SLC39A6's molecular function through recombinant protein studies may unveil novel therapeutic strategies for cancers and zinc-related disorders, highlighting its significance in both basic and translational research.
×
